JACC. Cardiovascular interventions · 2025
1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shishehbor Mehdi H, Zayed Hany, Dua Anahita, Mills Joseph L, Powell Richard J, Lee Arthur C, Bunte Matthew C, Stanley Gregory A, Sritharan Kaji, Clair Daniel G
Аннотация
BACKGROUND: Up to 20% of patients with chronic limb-threatening ischemia (CLTI) are ineligible or have exhausted conventional options of lower extremity revascularization ("no-option") and face high rates of major amputation and death.
OBJECTIVES: The authors present the 1-year outcomes of the pivotal PROMISE II trial and a patient-level pooled analysis combined with PROMISE I and PROMISE UK, comprising the largest cohort of prospectively studied patients following transcatheter arterialization of the deep veins (TADV) with the LimFlow System.
METHODS: The single-arm, multicenter prospective PROMISE II study included patients with Rutherford class 5/6 CLTI and independently assessed no-option status. Amputation-free survival (AFS), limb salvage, and survival were assessed through 1 year. Clinical outcomes included Rutherford classification, pain scores, and wound healing.
RESULTS: In PROMISE II, 105 enrolled patients had a median age of 70 years, 68.6% (72/105) were men, and the prevalence of comorbidities was high, including 77.1% (81/105) with diabetes. At 1 year, AFS was 54.2% (95% CI: 45.2-65.1%), limb salvage was 68.7% (95% CI: 59.8-78.9%), and survival was 79.0% (95% CI: 70.2-88.8%). The pooled analysis included 137 patients from PROMISE I, II, and UK and showed 1-year AFS of 66.1% (95% CI: 58.4-74.9%), limb salvage of 74.4% (95% CI: 67.1-82.5%), and survival of 88.9% (95% CI: 82.9-95.2%). Clinical symptoms and wound status showed improvement through 1 year.
CONCLUSIONS: 1-year outcomes following TADV with the LimFlow System demonstrated durable AFS and limb salvage rates, and improvement in clinical symptoms in no-option CLTI patients who often face major amputation or palliative care.
OBJECTIVES: The authors present the 1-year outcomes of the pivotal PROMISE II trial and a patient-level pooled analysis combined with PROMISE I and PROMISE UK, comprising the largest cohort of prospectively studied patients following transcatheter arterialization of the deep veins (TADV) with the LimFlow System.
METHODS: The single-arm, multicenter prospective PROMISE II study included patients with Rutherford class 5/6 CLTI and independently assessed no-option status. Amputation-free survival (AFS), limb salvage, and survival were assessed through 1 year. Clinical outcomes included Rutherford classification, pain scores, and wound healing.
RESULTS: In PROMISE II, 105 enrolled patients had a median age of 70 years, 68.6% (72/105) were men, and the prevalence of comorbidities was high, including 77.1% (81/105) with diabetes. At 1 year, AFS was 54.2% (95% CI: 45.2-65.1%), limb salvage was 68.7% (95% CI: 59.8-78.9%), and survival was 79.0% (95% CI: 70.2-88.8%). The pooled analysis included 137 patients from PROMISE I, II, and UK and showed 1-year AFS of 66.1% (95% CI: 58.4-74.9%), limb salvage of 74.4% (95% CI: 67.1-82.5%), and survival of 88.9% (95% CI: 82.9-95.2%). Clinical symptoms and wound status showed improvement through 1 year.
CONCLUSIONS: 1-year outcomes following TADV with the LimFlow System demonstrated durable AFS and limb salvage rates, and improvement in clinical symptoms in no-option CLTI patients who often face major amputation or palliative care.